Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Type 2 Diabetes Mellitus: Update Bulletin #3 [June 2018]

Product Code:
596200961
Publication Date:
June 2018
Format:
PDF
Price:
£910

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the type 2 diabetes mellitus (T2DM) market, including; Valeritas Holdings presenting positive data from a real-world, retrospective study; ENABLE, with their wearable insulin delivery device V-Go;OPKO Health’s initiation of a Phase IIb dose escalation study of pegapamodutide; and commencement of Oramed Pharmaceuticals Phase IIb study of its oral insulin capsule, ORMD-0801.

Business Questions:

• How do KOLs view V-Go’s efficacy claims and what are its key advantages?
• What concerns do KOLs have about V-Go insulin delivery device?
• What are the prospects of V-Go gaining reimbursement in Europe?
• Is there a future for wearable insulin delivery devices?
• According to the KOLs what are the main advantages and disadvantages of OPKO’s pegapamodutide?
• What evidence will be needed to ensure pegapamodutide’s commercial success?
• Where will pegapamodutide fit into the treatment pathway?
• What hurdles does ORMD-0801, Oramed’s oral insulin face in its development and commercialisation?
• Is there a place for ORMD-0801 in the current and future treatment of type 2 diabetes?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved